Restorative therapies for Parkinson's disease: Ethical issues

Restorative Therapies in Parkinson's Disease

Volumn , Issue , 2006, Pages 12-49

  Boer, Gerard J ^a  

^a NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77950606332     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-32823-2_2     Document Type: Chapter

References (142)

1. Advisory Group on the Ethics of Transplantation (1996) Animal tissues into humans. Her Majesty's Stationary Office, Norwich, UK.
2. Ahlskog, J.E., Muenter, M.D. (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16:448-58.
3. Albin, R.L. (2002) Sham surgery controls: intracerebral grafting of fetal tissue for Parkinson's disease and proposed criteria for use of sham surgery controls. J Med Ethics 28:322-5
4. Arendash, G.W. and Gorski, RA. (1982) Enhancement of sexual behavior in female rats by neonatal transplantation of brain tissue from males. Science 217:1276-1278.
5. Arjona, V., Minguez-Castellanos, A., Montoro, R.J., Ortega, A., Escamilla, F., Toledo-Aral, J.J., et al. (2003) Autotransplantation of human carotid body cell aggregates for treatment of Parkinson's disease. Neurosurgery 53:321-8
6. Armstrong, R.J. and Svendsen, C.N. (2000) Neural stem cells: from cell biology to cell replacement. Cell Transplant 9:139-52
7. Bach, F.H., Fishman, J.A., Daniels, N., Proimos, J., Anderson, B., Carpenter, C.B., Forrow, L., Robson, S.C. and Fineberg, H.V. (1998) Uncertainty in xenotransplantation: individual benefit versus collective risk. Nature Med 4:141-144.
8. Backlund, E-O., Granber, P-O., Hamberger, B., Sedvall, G., Seiger, A. and Olson, L. (1985) Transplantation of adrenal medullary tissue to striatum in parkinsonism: first clinical trials. J Neurosurg 62:169-173.
9. Bankiewicz, K., Mandel, R.J. and Sofroniew, M.V. (1993) Trophism, transplantation, and animal models of Parkinson's disease. Exp Neurol 124:140-149.
10. Barker, R.A., Kendall, A.L. and Widner, H. (2000) Neural tissue xenotransplantation: what is needed prior to clinical trials in Parkinson's disease? Neural Tissue Xenografting Project, Cell Transplant 9:235-46.
11. Beauchamp, T.L. and Childress, J.E. (1989) Principles of Biomedical Ethics. New York: Oxford University Press, Oxford, UK.
12. Benabid, A.L., Pollak, P., Gervason, C.L., Hoffmann, D., Gao, D.M., Hommel, M., et al. (1991) Long term suppression of tremor by chronic stimulation of the ventral intermediate nucleus thalamic nucleus. Lancet 337:403-6.
13. Benabid, A.L. (2003) Deep brain stimulation for Parkinson's disease. Curr Opin Neurobiol 13:696-706
14. Birnbacher, D. (1995) Identität der Persönlichkeit und Identität der Person: philosophische Fragen im Zusammenhang mit der Transplantation von Hirngewebe. Z Neurochir 5:180-185.
15. Björklund, A. (1992) Dopaminergic transplants in experimental parkinsonism: cellular mechanisms of graft-induced functional recovery. Current Opinion in Neurobiology 2:683-689.
16. Björklund, A., Dunnett,S.B., Brundin, P., Stoessl, A.J., Freed, C.R., Breeze, R.E., et al. (2003) Neural transplantation for the treatment of Parkinson's disease, Lancet Neurol 2:437-45.
17. Bjornson, C.R., Rietze, R.L., Reynolds, B.A., Magli, M.C., Vescovi A.L. (1999) Turning brain into blood: a hematopoietic fate adopted by adult neural stem cells in vivo. Science 283:534-7.
18. BMA guidelines on the use of fetal tissue. (1988) Lancet 1:1119.
19. Boer, G.J. (1994) Ethical guidelines for the use of human embryonic or fetal tissue for experimental and clinical neurotransplantation and research. J. Neurology 242;1-13.
20. Boer, G.J. (1996) The self-restraining ethical guidelines of NECTAR for the clinical neurotransplantation investigations. In: Hubig, C. and Poser, C. (eds.), Cognitio humana-Dynamik des Wissens und der Werte, XVII Deutscher Kongress für Philosophie, Leipzig; pp. 1420-7.
21. Boer, G.J. (1999) Ethical issues in neurografting of human embryonic cells. Theor Med Bioeth 20:461-75.
22. Boer, G.J. and Widner, H. (2002) Clinical neurotransplantation: core assessment protocol rather than sham surgery as control. Brain Res Bull 58:547-53.
23. Bopp, J. and Burtchaell, J.T. (1988) Report of the Human Fetal Tissue Research Panel, Vol 1. Washington: US Government Printing Office, pp. 45-71.
24. Borlongan, C.V. and Sanberg, P.R. (2002) Neural transplantation for treatment of Parkinson's disease. DDT 7:674-682
25. Brazelton, T.R., Rossi, F.M., Keshet, G.I. and Blau, H.M. (2000) From marrow to brain: expression of neuronal phenotypes in adult mice. Science 290:1775-9.
26. Brooks, D.J., Frey, K.A., Marek, K.L., Oakes, D., Paty, D., Prentice, R., Shults, C.W. and Stoessl, A.J. (2003) Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 184 Suppl 1:S68-79
27. Brundin, P., Karlsson, J., Emgard, M., Kaminski Schierle, G.S., Hansson, O., Petersen, A. and Castilho, R.F. (2000) Improving the survival of grafted dopaminergic neurons: a review over current approaches. Cell Transplantation 9:179-95.
28. Butler, D. (1998) Last chance to stop and think on risks of xenotransplants. Nature 391:320-324.
29. Calne, D.B. (1993) Treatment of Parkinson's disease, N Engl J Med 329:1021-7
30. Cibelli, J.B., Kiessling, A.A., Cunniff, K., Richards, C., Lanza, R.P., West, M.D. (2001) Somatic cell nucleus transfer in humans: pronuclear and early embryonic development. J Regen Med 2:25-31
31. Clark, P.A. (2002) Placebo surgery for Parkinson's disease: do the benefits outweigh the risks? J Law Med Ethics 30:58-68
32. CNESVS (National Consultative Ethics Committee for Life Sciences and Health) (1984) Recommendation on the Use of Embryo Tissue as well as Tissue of Dead Foetuses for Therapeutic, Diagnostic and Scientific Purposes. Le Comité, Paris.
33. CNESVS (National Consultative Ethics Committee for Life Sciences and Health) (1990) Statement on Intracerebral Graft of Mesencephalic Tissue of Human Embryo Origin in Patients with Parkinsonism for Therapeutic Experimentation. Le Comité, Paris.
34. Council of Europe (1997) Convention for the protection of human rights and dignity of the human being with regard to the application of biology and medicine. European Treaty Series 164.
35. CPMP Working Party on Efficacy of Medicinal Products (1990) EEC Note for Guidance: Good Clinical Practice for Trials on Medicinal Products in the European Community. Pharmacol Toxicol 67:361-72.
36. Daar, A.S. (1998) Analysis of factors for the prediction of the response to xenotransplantation. Ann NY Acad Sci 862:222-233.
37. Date, I., Shingo, T., Ohmoto, T. and Emerich, D.F. (1997) Long-term enhanced chromaffin cell survival and behavioral recovery in hemiparkinsonian rats with cografted polymer-encapsulated human NGF-secreting cells. Exp Neurol 147:10-7.
38. De La Fuente-Fernandez, R. and Stoessl, A.J. (2002) The biochemical bases for reward. Implications for the placebo effect. Eval Health Prof 25:387-98.
39. De Wert, G. (2002) The use of human embryonic stem cells for research: an ethical evaluation, Prog Brain Res 138:405-470
40. Deacon, T., Dinsmore, J., Costantini, L.C., Ratliff, J. and Isacson, O. (1998) Blastulastage stem cells can differentiate into dopaminergic and serotonergic neurons after transplantation. Exp Neurol 149:28-41
41. Defer, G.L., Widner, H,., Marie, R.M., Remy, P., Levivier, M. and Conference participants (1999) Core assessement program for surgical interventional therapies in Parkinsons' disease (CAPSIT-PD). Movement Disorder 14: 572-584.
42. Dekkers, W. and Boer, G. (2001) Sham neurosurgery in patients with Parkinson's disease: is it morally acceptable? J Med Ethics 27:151-6.
43. Donovan, P.J. and Gearhart, J. (2001) The end of the beginning for pluripotent stem cells. Nature 414:92-7.
44. Dunnett, S.B. and Björklund, A. (1999) Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399:A32-39.
45. Dunnett, S.B., Björklund, A. and Lindvall, O. (2001) Cell therapy in Parkinson's disease-stop or go?, Nat Rev Neurosci 2:365-9.
46. Dunning, J.J., White, D.J. and Wallwork, J. (1994) The rationale for xenotransplantation as a solution to the donor organ shortage. Pathol Biol 42:231-235.
47. During, M.J., Kaplitt, M.G., Stern, M.B. and Eidelberg, D. (2001) Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum Gene Ther 12:1589-91.
48. During, M.J., Samulski R.J., Elsworth, J.D., Kaplitt, M.G., Leone, P., Xiao, X., Li, J.;, Freese, A., Taylor, J.R., Roth, R.H., Sladek, J.R.; O-Malley, K.L. and Redmond, D.E. (1998) In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther 5:820-7.
49. Dutch Health Council (2002) Stem cells for tissue repair, 09E, The Hague, The Netherlands
50. EC Directive of the European Parliament and Council (2003) Setting standards of quality and safety for the donation, procurement, testing, processing, storage and distribution of human tissues and cells, 2002/0128 (COD), adopted A5-0387, Brussels, Belgium
51. Falkner, F. and Tanner, J.M. (eds.) (1978) Human Growth 1, Principles and Prenatal Growth. Baillière Tindall, London, UK.
52. Felten, D.L. (1994) Cell transplantation and research design. Science 263: 1546.
53. Flax, J.D., Aurora, S., Yang, C., Simonin, C., Wills, A.M., Billinghurst, L.L., Jendoubi, M., Sidman, R.L., Wolfe, J.H., Kim, S.U. and Snyder, E.Y. (1998) Engraftable human neural stem cells respond to developmental cues, replace neurons and express foreign genes. Nature Biotech 16:1033-1039
54. Freed, C.R., Greene, P.E., Breeze, R.E., Tsai, W.Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J.Q., Eidelberg, D. and Fahn, S. (2001) Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344:710-9.
55. Freed,W.J. (1991) Substantia nigra grafts and Parkinson's disease: from animal experiments to human therapeutics trials. Rest Neurol Neurosc 3:109-134
56. Freeman, T.B., Vawter, D.E., Leaverton, P.E., Godbold, J.H., Hauser, R.A., Goetz, C.G. and Olanow, C.W. (1999) Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease. N Engl J Med 341:988-92
57. Freese, A. (1999) Restorative gene therapy approaches to Parkinson's disease, Med Clin North Am 83:537-48
58. Frodl, E.M., Duan, W.M., Sauer, H., Kupsch, A. and Brundin, P. (1994) Human embryonic dopamine neurons xenografted to the rat: effects of cryopreservation and varying regional source of donor cells on transplant survival, morphology and function. Brain Res 647:286-298.
59. Gage, F.H., Björklund, A., Stenevi, U., Dunnett, S.B. and Kelly, P.A.T. (1984) Intrahippocampal septal grafts ameliorate learning impairments in aged rats. Science 225:533-536.
60. Galpern, W.R., Burns, L.H., Deacon, T.W., Dinsmore, J. and Isacson, O. (1996) Xenotransplantation of porcine fetal ventral meencephalon in a rat model of Parkinson's disease: functional recovery and graft morphology. Exp Neurol 140:1-13.
61. Gansbacher. B. (2003) European Society of Gene Therapy. Report of a second serious adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position of the European Society of Gene Therapy (ESGT), J. Gene Med 5:261-2
62. Gareth Jones, D. (1991) Fetal neural transplantation: placing the ethical debate within the context of society's use of human material. Bioethics 5:23-43.
63. Gill, S.S., Patel, N.K., Hotton, G.R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D.J., Svendsen, C.N. and Heywood, P. (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9:589-95.
64. Goetz, C.G., Janko, K., Blasucci, L., Jaglin, J.A. (2003) Impact of placebo assignment in clinical trials of Parkinson's disease. Mov Disord 18:1146-9.
65. Hagell, P., Piccini, P., Björklund, A., Brundin, P., Rehncrona, S.,Widner, H., Crabb, L., Pavese, N., Oertel,W.H., Quinn, N., Brooks, D.J. and Lindvall, O. (2002) Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci 5:627-8.
66. Hansen, J.E. (2002) Embryonic stem cell production through therapeutic cloning has fewer ethical problems than stem cell harvest from surplus IVF embryos. J Med Ethics 28:86-8.
67. Harrower, T.P. and Barker, R.A. (2004) The emerging technologies of neural xenografting and stem cell transplantation for treating neurodegenerative disorders, Drugs Today 40:171-89.
68. Heneine, W., Tibell, A., Switzer, W.M., Sandstrom, P., Rosales, G.V., Mathews, A., Korsgren, O., Chapman, L.E., Folks, T.M. and Groth, C.G. (1998) No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts. Lancet 352:695-9.
69. HER (Working Group on Human Embryos and Research) (1994) Second Report, EC Directorate General XII, Science Research and Development, Brussels.
70. Hermens, W.T. and Verhaagen, J. (1998) Viral vectors, tools for gene transfer in the nervous system. Prog Neurobiol 55:399-432.
71. HMSO (Her Majesty's Stationary Office) (1989) Review of the guidance on the research and use of fetuses and fetal material (Polkinghorne rapport) London, Cm 762.
72. Huffaker, T.K. Boss, B.D., Morgan, A.S., Neff, N.T., Strecker, R.E., Spence, M.S. and Miao, R. (1989) Xenografting of fetal pig ventral mesencephalon corrects motor asymmetry in the rat model of Parkinson's disease. Exp Brain Res 77:329-336.
73. Hwang, W.S., Ryu, Y.J., Park, J.H., Park, E.S., Lee, E.G., Koo, J.M., Jeon, H.Y., Lee, B.C., Kang, S.K., Kim, S.J., Ahn, C., Hwang, J.H., Park, K.Y., Cibelli, J.B. and Moon, S.Y. (2004) Evidence of a pluripotent human embryonic stem cell line derived from a cloned blastocyst. Science 303:1669-74.
74. Isacson, O., Deacon, T.W., Pakzaban, P., Galpern, W.R., Dinsmore, J. and Burns, L.H. (1995) Transplanted xenogeneic neural cells in neurodegenerative disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres. Nature Med 11:1189-1194.
75. Isacson, O. and Breakefield, X.O. (1997) Benefits of hosting animal cells in the human brain. Nature Med 3:964-969.
76. Itakura, T., Uematsu, Y., Nakao, N., Nakai, E. and Nakai, K. (1997) Transplantation of autologous sympathetic ganglion into the brain with Parkinson's disease. Long-term follow-up of 35 cases. Stereotact Funct Neurosurg 69:112-5.
77. Kirik, D., Georgievska, B. and Björklund, A. (2004) Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat Neurosci 7:105-10.
78. Koller, W.C. (ed.) (1987). Handbook of Parkinson's Disease. Dekker, New York.
79. Kordower, J.H., Bloch, J., Ma, S.Y., Chu, Y., Palfi, S., Roitberg, B.Z., Emborg, M., Hantraye, P., Deglon, N. and Aebischer, P. (1999) Lentiviral gene transfer to the nonhuman primate brain. Exp Neurol 160:1-16.
80. Kordower, J.H., Emborg, M.E., Bloch, J., Ma, S.Y., Chu, Y., Leventhal, L., et al. (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290:767-73.
81. Langston, J.W.,Widner, H., Goetz, C.G., Brooks, D., Fahn, S. and Freeman, T. (1992) Core assessment program for intracerebral transplantation (CAPIT). Movement Disorders 7:2-13.
82. Larsson, L.C., Frielingsdorf, H., Mirza, B., Hansson, S.J., Anderson, P., Czech, K.A., Strandberg, M. and Widner, H. (2001) Porcine neural xenografts in rats and mice: donor tissue development and characteristics of rejection. Exp Neurol 172:100-14.
83. Coffman, K.L., Sher, L., Hoffman, A., Rojter, S., Folk, P., Cramer, D.V., Vierling, J., Villamel, F., Podesta, L., Demetriou, A. and Makowka, L. (1998) Survey results of transplant patient's attitudes on xenografting. Psychosometics 39:379-383.
84. Le, H.N. and Frim, D.M. (2002) Gene therapy for Parkinson's disease. Expert Opin Biol Ther 2:151-61.
85. Lindvall, O. (1999). Cerebral implantation in movement disorders: state of the art. Movement Disorders 14:201-5.
86. Linke, D.B. (1993). Hirnverpflanzung. Rowoldt, Reinbek bei Hamburg.
87. London, A.J. and Kadane, J.B. (2002) Placebos that harm: sham surgery controls in clinical trials, Stat Meth Med Res 11:413-427
88. Macklin, R. (1999) The ethical problems with sham surgery in clinical research. N Engl J Med 341:992-6
89. Madrazo, I., Drucker-Colin, R., Diaz, V., Martinez-Mata, J., Torres, C. and Becerril, J.J. (1987) Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson's disease. New Engl J Med 316:831-4.
90. Martin, U., Kiessig, V., Blusch, J.H., Haverich, A., Von der Helm, K., Herden, T. and Steinhoff, G. (1998) Expression of pig endogenous retrovirus by primary porcine endothelial cells and infection of human cells. Lancet 352:692-694.
91. Matthiesen, L. (2002) Survey on opinions from national committees or similar bodies, public debate and national legislation in relation to human embryonic stem cell research and use, Vol 1-2, EC Research Directorate-General, Brussels.
92. McCullagh, P.M. (1987) The Foetus as Transplant Donor. Scientific, Social and Ethical Perspectives. Wiley, Chichester.
93. McLaren, A. (1996) Research on embryos in vitro, the various types of research. Third Symposium on Bioethics 'Medically assited procreation and the protection of the human embryo' CDBI/SPK 22, Council of Europe, Strasbourg December 15-18.
94. McLaren, A. (2001) Ethical and social considerations of stem cell research. Nature 414: 129-31.
95. McRae, C., Cherin, E., Diem, G., Vo, A.H., Ellgring, J.H., Russell, D., Fahn, S. and Freed, C. (2003) Does personality change as a result of fetal tissue transplantation in the brain? J Neurol 250:282-6.
96. Mezey, E., Chandross, K.J., Harta, G., Maki, R.A. and McKercher, S.R. (2000) Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow. Science 290:1779-82.
97. Nakao, N., Kakishita, K., Uematsu, Y., Yoshimasu, T., Bessho, T., Nakai, K., Naito, Y. and Itakura, T. (2001) Enhancement of the response to levodopa therapy after intrastriatal transplantation of autologous sympathetic neurons in patients with Parkinson disease. J Neurosurg 95:275-84.
98. Nasto, B. (1997) Xenotransplant firms get xenophobic. Nature Biotech 15.
99. Normile, D., Vogel, G., Couzin, J. (2006) South Korean team's remaning human stem cell claim demolished. Science 311:156-157.
100. Normile, D., Vogel, G., Couzin, J. (2006) South Korean team's remaning human stem cell claim demolished. Science 311:156-157.
101. Northoff, G. (1996) Do brain tissue transplants alter personal identity? Inadequacies of some "standard" arguments. J Med Ethics 22:174-180.
102. Nuffield Council on Bioethics. (1996) Animal-to-human transplants. London, UK.
103. Nuffield Council on Bioethics (2000) Stem cell therapy: the ethical issues. Dorchester,UK
104. Oduncu, F.S. (2003) Stem cell research in Germany: ethics of healing vs. human dignity. Med Health Care Philos 6:5-16.
105. O'Rahilly, R. and Müller, F. (1987) Developmental Stages in Human Embryos. Carnegie Institution of Washington, Washington.
106. Ostrosky-Solis, F., Quintanar, L., Madrazo, I., Drucker-Colin, R., Franco-Bourland, R. and Leon-Meza, V. (1988) Neuropsychological effects of brain autograft of adrenal medullary tissue for the treatment of Parkinson's disease. Neurology 38:1442-50.
107. Outka, G. (2002) The ethics of human stem cell research. Kennedy Inst Ethics J 12:175-213.
108. Palacios, R, Golunski, E. and Samaridis, J. (1995) In vitro generation of hematopoietic stem cells from an embryonic stem cell line. Proc Natl Acad Sci USA 92:7530-4.
109. Patience, C., Takeuchi, Y. and Weiss, R.A. (1997) Infection of human cells by an endogenous retrovirus of pigs. Nature Med 3:282-286.
110. Peel report, Department of Health and Social Security. (1972) The Use of Fetuses and Fetal Material for Research, Report of the Advisory Group. Her Majesty's Stationary Office, London.
111. Peschanski, M., Defer, G.L., Dethy, S., Hantraye, P.M., Levivier, M., Nguyen, J.P. and Cesaro, P. (1999) The need for phase III studies in experimental surgical treatments of Parkinson's disease. Adv Neurol 80:651-3.
112. Piccini, P., Brooks, D.J., Björklund, A., Gunn, R.N., Grasby, P.M., Rimoldi, O., et al. (1999) Dopaminergic release from nigral transplants visualized in vivo in a Parkinson's patient. Nature Neuroscience 2:1137-40.
113. Polgar, S., Morris, M.E., Reilly, S., Bilney, B. and Sanberg, P.R. (2003) Reconstructive neurosurgery for Parkinson's disease: a systematic review and preliminary metaanalysis, Brain Res Bull 60:1-24
114. Ralph, M.R., Foster, R.G., Davis, F.C. and Menaker, M. (1990) Transplanted suprachiasmatic nucleus determines circadian period. Science 247:975-978.
115. Raymon, H.K., Thode, S. and Gage, F.H. (1997) Application of ex vivo gene therapy in the treatment of Parkinson's disease. Exp Neurol 144:82-91
116. Robertson, J.A. (1988) Rights, symbolism and public policy in fetal tissue transplants. Hastings Center Report 6.
117. Rohwedel, J., Guan, K., Zuschratter, W., Jin, S., Ahnert-Hilger, G., Furst, D., Fassler, R. and Wobus, A.M. (1998) Loss of beta1 integrin function results in a retardation of myogenic, but an acceleration of neuronal, differentiation of embryonic stem cells in vitro. Dev Biol 201:167-84.
118. Romijn, H. (1997) About the origin of consciousness. A new, multidiciplinary perspective on the relationship between brain and mind. Proc Kon Akad Wetensch 100:181-267.
119. Sanberg, P.R., Borlongan, C.V., Othberg, A.I., Saporta, S., Freeman, T.B. and Cameron, D.F. (1997) Testis-derived Sertoli cells have a trophic effect on dopamine neurons and alleviate hemiparkinsonism in rats. Nat Med 3:1129-32
120. Scothorne, R.J. (1968) Early development. In Passmore, R., and Robson, J.S. (eds.): A Companion to Medical Studies, Vol 1, Ch 18, Blackwell Scientific Publications, Oxford.
121. Shamblott, M.J., Axelman, J., Littlefield, J.W., Blumenthal, P.D., Huggins, G.R., Cui, Y., Cheng, L. and Gearhart, J,D, (2001) Human embryonic germ cell derivatives express a broad range of developmentally distinct markers and proliferate extensively in vitro. Proc Natl Acad Sci USA 98:113-8.
122. Shen, Y., Muramatsu, S.I., Ikeguchi, K., Fujimoto, K.I., Fan, D.S., Ogawa, M., et al. (2000) Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum. Gene Ther 11:1509-19.
123. Shetty, N., Friedman, J.H., Kieburtz, K., Marshall, F.J. and Oakes, D. (1999) The placebo response in Parkinson's disease. Parkinson Study Group. Clin Neuropharmacol 22:207-12
124. Singer, P. (1990) Embryo Experimentation. Ethical, Legal and Social Issues. Cambridge University Press, Cambridge.
125. Stoye, J.P., Le Tissier, P., Takeuchi, Y., Patience, C. and Weiss, R.A. (1998) Endogenous retrovirus: a potential problem for xenotransplantation? Ann NY Acad Sci 862:67-74.
126. Slevin, J.T., Gerhardt, G.A., Smith, C.D., Gash, D.M., Kryscio, R., Young, B. (2005) Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 102:216-222.
127. Tasker, R.R, Siqueira, J., Hawrrylyshyn, P. and Organ, L.W. (1983) What happened to VIM thalamotomy for Parkinson's disease. Appl Neurophysiol 46:68-83.
128. Taylor, H., Minger, S.L., (2005) Regenerative medicine in Parkinson's disease: generation of mesencephalic cells from embryonic stem cells. Curr Opin Biotechnol 16:487-492.
129. Tenenbaum, L., Lehtonenm, E. and Monahanm, P.E. (2003) Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr Gene Ther 3:545-65.
130. Thomson, J.A, Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A., Swiergiel, J.J., Marshall, V.S. et al. (1998) Embryonic stem cell lines derived from human blastocysts. Science 282:1145-1147.
131. Toma, J.G, Akhavan, M., Fernandes, K.J., Barnabe-Heider, F., Sadikot, A., Kaplan, D.R., et al (2001) Isolation of multipotent adult stem cells from the dermis of mammalian skin, Nat Cell Biol 3:778-84.
132. United Nations (1948) Universal declaration of human rights. Yearbook of the United Nations 1948-49. Dept of Public Information, United Nations, New York.
133. Walters, L. (1988) Ethical issues in fetal research: a look back and a look forward. Clin Res 36:209-214.
134. Webster, R.G., Guan, Y., Poon, L., Kraus, S.,Webby, R., Govorkoval, E. et al (2005) The spread of the H5N1 bird flu epidemie in Asia in 2004. Arch Virol Suppl 19:117-129.
135. Weiss, R.A. (1998) Transgenic pigs and virus adaptation. Nature 391:327-328.
136. Weissman, I.L. (2002) Stem cells-scientific, medical, and political issues. N Engl J Med 346:1576-9.
137. Widner, H. (1994) NIH neural transplantation funding. Science 263:737.
138. Widner, H. and Defer, G.L. (1999) Dyskinesias Assessment: From CAPIT to CAPSIT. Movement Disorders 14 Suppl 1:60-66.
139. Wilmut, I., Schnieke, A.E., McWhir, J., Kind, A.J. and Campbell, K.H. (1997) Viable offspring derived from fetal and adult mammalian cells. Nature 385:810-813.
140. Wolf, E., Zakhartchenko, V. and Brem, G. (1998) Nuclear transfer in mammals: recent developments and future perspectives. J Biotechnol 65:99-110.
141. World Medical Association Declaration of Helsinki (2000) Ethical principles for medical research involving human subjects. JAMA 284:3043-5.
142. Zurn, A.D., Tseng, J. and Aebischer, P. (1996) Treatment of Parkinson's disease. Symptomatic cell therapies: cells as biological minipumps. Eur Neurol 36:405-8.